

Raashid Ahmed Luqmani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4524453/publications.pdf>

Version: 2024-02-01

158
papers

20,871
citations

34105

52
h-index

9861

141
g-index

160
all docs

160
docs citations

160
times ranked

10398
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2022, 74, 1013-1018.	3.4	4
2	Response to: "Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues"™ by Ghajari and Sabour. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e106-e106.	0.9	2
3	The role of neutrophils in rheumatic disease-associated vascular inflammation. <i>Nature Reviews Rheumatology</i> , 2022, 18, 158-170.	8.0	32
4	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 386-392.	5.6	50
5	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	5.6	71
6	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 400-406.	5.6	62
7	P115 Remote clinical management: incorporating electronic assessment of patients with rheumatic diseases into standard clinical pathways and comparison to in-person assessment. <i>Rheumatology</i> , 2022, 61, .	1.9	1
8	Pulmonary involvement in primary systemic vasculitides. <i>Rheumatology</i> , 2021, 61, 319-330.	1.9	16
9	P211 Aortitis: clinical experience within a tertiary centre. <i>Rheumatology</i> , 2021, 60, .	1.9	0
10	P203 Incidence, characteristics and determinants of severe infections in patients with anti-neutrophil cytoplasm antibody-associated vasculitis receiving rituximab therapy: a single centre study. <i>Rheumatology</i> , 2021, 60, .	1.9	0
11	Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1475-1482.	0.9	34
12	Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1713-1719.	5.6	35
13	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021, 60, 617-628.	1.9	22
14	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. <i>Rheumatology</i> , 2021, 60, 4361-4366.	1.9	15
15	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
16	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
17	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 667-676.	5.6	33
18	Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. <i>Rheumatology</i> , 2020, 59, 2316-2324.	1.9	34

#	ARTICLE	IF	CITATIONS
19	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 2299-2307.	1.9	21
20	Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 393-399.	0.9	77
21	EP03â€fAn audit of glucocorticoid prescription in patients with giant cell arteritis. <i>Rheumatology</i> , 2020, 59, .	1.9	0
22	A hidden lung cancer in a patient with granulomatosis with polyangiitis. <i>BJR case Reports</i> , 2020, 6, 20190114.	0.2	2
23	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3717-3726.	1.9	26
24	Comment on: Diagnosis of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e119-e121.	1.9	0
25	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. <i>Rheumatology and Therapy</i> , 2020, 7, 793-810.	2.3	30
26	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
27	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	1.9	56
28	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	1.9	128
29	Diagnosis of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, iii5-iii16.	1.9	58
30	ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies. <i>JCI Insight</i> , 2020, 5, .	5.0	53
31	Early development of new cardiovascular risk factors in the systemic vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 126-134.	0.8	2
32	Magnetic resonance angiography versus 18F-fluorodeoxyglucose positron emission tomography in large vessel vasculitis. <i>Autoimmunity Reviews</i> , 2019, 18, 102405.	5.8	19
33	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	5.6	82
34	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	2.0	6
35	FRIO284â€...RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
36	THU0286â€...MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
37	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open, 2019, 5, e001003.	3.8	52
38	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open, 2019, 5, e001020.	3.8	56
39	Small- and Medium-Vessel Primary Vasculitis. , 2019, , 789-807.e1.		0
40	Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212713.	0.9	38
41	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. Rheumatology, 2018, 57, 227-235.	1.9	101
42	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	5.6	200
43	i128â€fImproving value projects. Rheumatology, 2018, 57, .	1.9	0
44	Preface. Best Practice and Research in Clinical Rheumatology, 2018, 32, 1-2.	3.3	1
45	035â€fAortic dissection secondary to giant cell arteritis in a patient on tocilizumab for established seronegative rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	1
46	Clinical features and structured clinical evaluation of vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 31-51.	3.3	31
47	Making the most of the waiting room: Electronic patient engagement, a mixed methods study. Digital Health, 2018, 4, 205520761775130.	1.8	3
48	050â€fIgG4 related disease causing left anterior descending artery stenosis successfully treated with rituximab therapy. Rheumatology, 2018, 57, .	1.9	1
49	The use of ultrasound in the management of large-vessel vasculitis: an evolving concept. Clinical and Experimental Rheumatology, 2018, 36 Suppl 114, 96-102.	0.8	1
50	Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?. RMD Open, 2017, 3, e000353.	3.8	12
51	The RUDY study: using digital technologies to enable a research partnership. European Journal of Human Genetics, 2017, 25, 816-822.	2.8	39
52	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	27.0	682
53	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23
54	Polyarteritis Nodosa and Related Disorders. , 2017, , 1559-1570.		1

#	ARTICLE	IF	CITATIONS
55	333.â€fTHE ROLE OF ULTRASOUND IN THE MANAGEMENT OF GIANT CELL ARTERITIS IN ROUTINE CLINICAL PRACTICE. <i>Rheumatology</i> , 2017, 56, .	1.9	0
56	Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	11
57	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1583-1594.	0.9	940
58	Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. <i>Journal of Rheumatology</i> , 2016, 43, 1085-1092.	2.0	24
59	Cryofibrinogenaemiaâ€”a neglected disease. <i>Rheumatology</i> , 2016, 56, kew379.	1.9	8
60	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. <i>Health Technology Assessment</i> , 2016, 20, 1-238.	2.8	313
61	Giant cell arteritis: Current treatment and management. <i>World Journal of Clinical Cases</i> , 2015, 3, 484.	0.8	50
62	O18.â€fEarly Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis. <i>Rheumatology</i> , 2015, , .	1.9	0
63	Disease assessment in systemic vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i76-82.	0.7	8
64	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1178-1182.	0.9	217
65	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	1.9	104
66	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.9	214
67	Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: AÂˆNICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2014, 32, 1171-1183.	3.3	12
68	State of the Art in the Treatment of Systemic Vasculitides. <i>Frontiers in Immunology</i> , 2014, 5, 471.	4.8	24
69	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 2306-2309.	1.9	246
70	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 953-956.	1.9	38
71	Current Status of Outcome Measure Development in Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 593-598.	2.0	31
72	Explaining fatigue in ANCA-associated vasculitis. <i>Rheumatology</i> , 2013, 52, 1680-1685.	1.9	50

#	ARTICLE	IF	CITATIONS
73	Maintenance of clinical remission in ANCA-associated vasculitis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 127-132.	8.0	17
74	2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. <i>Arthritis and Rheumatism</i> , 2013, 65, 1-11.	6.7	4,839
75	Update on the classification of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 3-17.	3.3	34
76	Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update. <i>British Journal of General Practice</i> , 2013, 63, 553-554.	1.4	7
77	Polyarteritis Nodosa and Related Disorders. , 2013, , 1498-1507.		1
78	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 484-492.	0.9	451
79	Large vessel vasculitides. <i>Current Opinion in Cardiology</i> , 2012, 27, 578-584.	1.8	15
80	Diagnosis and management of ANCA associated vasculitis. <i>BMJ: British Medical Journal</i> , 2012, 344, e26-e26.	2.3	100
81	Patient-reported Outcomes in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2012, 39, 795-803.	2.0	64
82	Damage Assessment in ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2012, 14, 494-500.	4.7	42
83	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2012, 51, 634-643.	1.9	102
84	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 955-960.	0.9	348
85	Recurrent inflammatory stenosis of the M1 segment: diagnostic and therapeutic considerations. <i>Neuroradiology</i> , 2012, 54, 529-532.	2.2	0
86	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatism</i> , 2012, 64, 943-954.	6.7	273
87	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 344-353.	6.4	182
88	Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S162-8.	0.8	13
89	Systemic vasculitis--is it time to reclassify?. <i>Rheumatology</i> , 2011, 50, 643-645.	1.9	41
90	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 704-704.	0.9	106

#	ARTICLE	IF	CITATIONS
91	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.9	47
92	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 488-494.	0.9	719
93	Pulmonary-renal syndromes: An update for respiratory physicians. <i>Respiratory Medicine</i> , 2011, 105, 1413-1421.	2.9	34
94	The Need for Diagnostic Criteria in Systemic Vasculitis. <i>Current Immunology Reviews</i> , 2011, 7, 394-401.	1.2	0
95	Nomenclature and classification of vasculitis – update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS). <i>Clinical and Experimental Immunology</i> , 2011, 164, 11-13.	2.6	76
96	Long-term damage to the ENT system in Wegener's granulomatosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 733-739.	1.6	17
97	Time to focus on outcome assessment tools for childhood vasculitis. <i>Pediatric Rheumatology</i> , 2011, 9, 29.	2.1	4
98	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011, 63, 588-596.	3.4	147
99	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Care and Research</i> , 2011, 63, 1055-1061.	3.4	63
100	Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 863-864.	6.7	244
101	Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2011, 50, 2214-2222.	1.9	91
102	Granulomatosis with Polyangiitis (Wegener's). <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 587-588.	6.1	49
103	BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 2311-2313.	1.9	42
104	Mortality in Wegener's granulomatosis: a bimodal pattern. <i>Rheumatology</i> , 2011, 50, 697-702.	1.9	69
105	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. <i>Rheumatology</i> , 2011, 50, 899-905.	1.9	89
106	An approach to the diagnosis and management of systemic vasculitis. <i>Clinical and Experimental Immunology</i> , 2010, 160, 143-160.	2.6	38
107	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010, 49, 1197-1199.	1.9	49
108	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. <i>Rheumatology</i> , 2010, 49, 2217-2219.	1.9	187

#	ARTICLE	IF	CITATIONS
109	Outcome Measures in ANCA-associated Vasculitis. Rheumatic Disease Clinics of North America, 2010, 36, 587-607.	1.9	12
110	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010, 363, 211-220.	27.0	1,471
111	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
112	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology, 2010, , .	1.9	1
113	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. Journal of Rheumatology, 2009, 36, 2362-2368.	2.0	35
114	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2009, 68, 1125-1130.	0.9	72
115	Pharmacotherapy of vasculitis. Expert Opinion on Pharmacotherapy, 2009, 10, 1273-1289.	1.8	12
116	Assessment of damage in vasculitis: expert ratings of damage. Rheumatology, 2009, 48, 823-827.	1.9	34
117	Cardiovascular involvement in primary systemic vasculitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 419-428.	3.3	24
118	Pleural Wegener's granulomatosis: a rare presentation. Histopathology, 2009, 54, 391-393.	2.9	3
119	Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the Rheumatic Diseases, 2009, 68, 1827-1832.	0.9	825
120	Developing multidisciplinary guidelines for the management of early rheumatoid arthritis. Musculoskeletal Care, 2008, 6, 97-107.	1.4	17
121	Assessment of systemic vasculitis. Autoimmunity Reviews, 2008, 8, 170-175.	5.8	13
122	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the Rheumatic Diseases, 2008, 67, 1004-1010.	0.9	343
123	Development of comprehensive disease assessment in systemic vasculitis. Postgraduate Medical Journal, 2008, 84, 143-152.	1.8	91
124	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 569-570.	0.9	2
125	Update on the use of biologics in primary systemic vasculitides. Expert Review of Clinical Immunology, 2007, 3, 901-911.	3.0	0
126	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.9	524

#	ARTICLE	IF	CITATIONS
127	Outpatient assessment of systemic vasculitis. Best Practice and Research in Clinical Rheumatology, 2007, 21, 713-732.	3.3	23
128	Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are We Any Further Forward?. Annals of Internal Medicine, 2007, 146, 674.	3.9	14
129	Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). Rheumatology, 2006, 45, 649-652.	1.9	28
130	The role of biologic therapies in the management of systemic vasculitis. Autoimmunity Reviews, 2006, 5, 273-278.	5.8	19
131	How to diagnose and treat secondary forms of vasculitis. Best Practice and Research in Clinical Rheumatology, 2005, 19, 321-336.	3.3	27
132	Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 2005, 52, 2461-2469.	6.7	723
133	Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?. Annals of the Rheumatic Diseases, 2005, 65, 841-844.	0.9	20
134	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Journal of Rheumatology, 2005, 32, 2488-95.	2.0	32
135	Disease assessment in systemic vasculitis. APLAR Journal of Rheumatology, 2004, 7, 150-157.	0.2	0
136	Assessing disease activity in the systemic vasculitides. Current Opinion in Rheumatology, 2002, 14, 23-28.	4.3	22
137	Maternal Stressors, Maternal Wellbeing and Children's Wellbeing in the Context of Juvenile Idiopathic Arthritis. Early Child Development and Care, 2002, 172, 89-98.	1.3	27
138	Measuring disease activity and outcomes in clinical studies.. Cleveland Clinic Journal of Medicine, 2002, 69, S11100-S11100.	1.3	2
139	Evaluation of vasculitis disease activity in Europe. European Journal of Internal Medicine, 2001, 12, 401-402.	2.2	8
140	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis and Rheumatism, 2001, 44, 912-920.	6.7	400
141	Introduction to, and classification of, the systemic vasculitides. Best Practice and Research in Clinical Rheumatology, 2001, 15, 187-202.	3.3	18
142	The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 615-621.	0.5	61
143	Medical student appraisal of interactive computer-assisted learning programs embedded in a general pathology course. Journal of Pathology, 2000, 191, 462-465.	4.5	18
144	Pseudoporphyria and Nonsteroidal Antiinflammatory Agents in Children with Juvenile Idiopathic Arthritis. Pediatric Dermatology, 2000, 17, 480-483.	0.9	41

#	ARTICLE	IF	CITATIONS
145	Is it possible to offer evidence-based treatment for systemic vasculitis?: Editorial review. Scandinavian Journal of Rheumatology, 2000, 29, 211-215.	1.1	7
146	Medical student appraisal of interactive computer-assisted learning programs embedded in a general pathology course. Journal of Pathology, 2000, 191, 462-465.	4.5	1
147	Optimisation of Cyclophosphamide Therapy in Systemic Vasculitis. Clinical Pharmacokinetics, 1998, 34, 79-90.	3.5	16
148	Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Rheumatology, 1998, 37, 57-63.	1.9	89
149	Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 401-409.	0.5	199
150	Damage occurs early in systemic vasculitis and is an index of outcome. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 391-399.	0.5	104
151	10 Disease assessment and management of the vasculitides. Bailliere's Clinical Rheumatology, 1997, 11, 423-446.	1.0	97
152	Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis and Rheumatism, 1997, 40, 371-380.	6.7	497
153	Clinical Pharmacology and Modification of Autoimmunity and Inflammation in Rheumatoid Disease. Drugs, 1994, 47, 259-285.	10.9	7
154	CORRELATION OF BLOOD LEVELS OF SOLUBLE VASCULAR CELL ADHESION MOLECULE-1 WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND VASCULITIS. Rheumatology, 1994, 33, 1112-1116.	1.9	78
155	Treatment of vasculitis in rheumatoid arthritis. Annales De Médecine Interne, 1994, 145, 566-76.	0.2	1
156	Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM - Monthly Journal of the Association of Physicians, 1994, 87, 671-8.	0.5	611
157	Classical versus non-renal Wegener's granulomatosis. The Quarterly Journal of Medicine, 1994, 87, 161-7.	1.0	43
158	Relapses in patients with a systemic vasculitis. The Quarterly Journal of Medicine, 1993, 86, 779-89.	1.0	77